Journal: Carcinogenesis
Article Title: Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts
doi: 10.1093/carcin/bgv146
Figure Lengend Snippet: Validation of differential methylated promoters and the prognostic value of EDARADD in NSCLC with high stromal mesenchymal expression in-vivo . ( A ) DNA methylation of selected genes measured by pyrosequencing in TAFs and paired CFs from 12 patients. ( B ) Fold (TAFs/CFs) relative mRNA expression of selected genes in five randomized patients by qRT-PCR. Horizontal dashed lines here and thereafter are added as a reference. ( C ) Kaplan–Meier survival curve using publicly available data of a cohort of 204 NSCLC patients (161 ADC, 43 SCC) sorted by their EDARADD DNA methylation status assessed in primary tumoral DNA . ( D ) Kaplan–Meier survival curve using publicly available data of a cohort of 226 NSCLC patients (226 ADC) sorted by their EDARADD expression assessed in primary tumors . ( E ) Representative images of histologic sections from our cohort stained for EDARADD obtained from unaffected lung parenchyma (control, left) or tumor (right). Black arrows within inserts point to EDARADD+ spindle-shaped mesenchymal cells. ( F ) Scoring of EDARADD protein expression in (non-endothelial) spindle-shaped stromal cells in our cohort of 20 NSCLC patients (10 ADC, 10 SCC).
Article Snippet: In the present study, we interrogated for the first time the DNA methylation landscape changes between CFs and paired TAFs from surgical patients with early stage NSCLC using the high-resolution Infinium 450K DNA Methylation Array.
Techniques: Biomarker Discovery, Methylation, Expressing, In Vivo, DNA Methylation Assay, Quantitative RT-PCR, Staining, Control